New antibody drug aims to prevent strokes in irregular heartbeat
NCT ID NCT07626411
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This large phase 3 trial tests an experimental drug, REGN7508, against the standard blood thinner apixaban for preventing strokes in people with atrial fibrillation (an irregular heartbeat). The study will enroll over 15,000 participants to compare how well each drug prevents strokes and serious bleeding. The goal is to see if REGN7508 is a safe and effective alternative.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
REGN7508 (cenvacibart), a monoclonal antibody
What this could lead to
If successful, this could offer a new, potentially safer option for preventing strokes in people with atrial fibrillation.
What could go wrong
This is a large phase 3 trial, but the drug is still experimental. It may not prove safer or more effective than apixaban, and there is a risk of unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••